Balanced US-focused mix blending growth value and dividends with efficient risk return characteristics
Report created on Aug 5, 2026Risk profile
4/7
Diversification profile
3/5
Positions
-
IT Ishares Lifepath Target Date 2055 ETF
ITDG - US46438G7604 30.00% -
SC Schwab U.S. Dividend Equity ETF
SCHD - US8085247976 30.00% -
SC Schwab U.S. Large-Cap Growth ETF
SCHG - US8085243009 23.00% -
AV Avantis® U.S. Small Cap Value ETF
AVUV - US0250728773 17.00%
This portfolio is built from four US-listed equity ETFs, with a small embedded bond slice inside the target-date fund. Roughly a third sits in a LifePath 2055 glidepath fund, about a third in a US dividend equity ETF, and the rest split between large-cap growth and small-cap value. That mix creates a blend of growth, income, and broad market exposure in a relatively simple structure. Because everything is fund-based rather than single stocks, day‑to‑day management is handled inside each ETF. This structure means most portfolio decisions happen at the “building block” level — choosing these four funds and their weights — while the internal holdings, sectors, and styles are diversified and adjusted by the ETF providers.
Growth
Over the 2023‑10‑19 to 2026‑08‑03 period, a $1,000 investment grew to about $1,755, a compound annual growth rate (CAGR) of 22.52%. CAGR is like your average speed on a long road trip, smoothing bumps along the way. This trailed both the US market and global market by around 1–1.4 percentage points per year, but the gap is modest. The maximum drawdown, or worst peak‑to‑trough fall, was about ‑19%, similar to the US market. It took roughly four months to bottom and three months to recover, showing that while declines were meaningful, they were not unusually deep or prolonged compared with broad markets.
Projection
The Monte Carlo simulation projects many possible 15‑year paths based on historical behavior. Monte Carlo is like running 1,000 alternate weather forecasts, then seeing how often it’s sunny, rainy, or stormy. Here, the median outcome turns $1,000 into about $2,860, implying an 8.46% average annual return across all simulations. The middle half of outcomes spans roughly $1,925 to $4,462, with a 77.7% chance of finishing positive. The wide $1,021–$8,215 “possible range” shows how uncertain long‑term investing can be. These numbers are illustrative only: they lean on past data and assumptions that may not match future markets.
Asset classes
- Stocks 99%
- Bonds 1%
Asset‑class exposure here is very straightforward: about 99% stocks and 1% bonds, mainly via the LifePath 2055 ETF. That makes this much more of an equity portfolio than a traditional “balanced” 60/40 mix. Stocks typically drive long‑term growth but also most of the volatility — the ups and downs — while bonds usually act as a stabilizer. With so little in bonds, the portfolio’s behavior will be closely tied to equity markets, especially US stocks. This stock‑heavy structure can be effective for growth, but it also means that downturns in the stock market will flow through quite directly to portfolio performance.
Sectors
- Technology 24%
- Financials 15%
- Health Care 12%
- Consumer Discretionary 10%
- Industrials 9%
- Consumer Staples 9%
- Energy 8%
- Telecommunications 8%
- Basic Materials 2%
- Real Estate 1%
- Utilities 1%
Sector exposure is diversified, with technology the largest slice at 24%, followed by financials, health care, consumer areas, energy, and others. This spread is relatively balanced and not extremely tech‑heavy compared with many US indices, which is a positive sign for diversification. Each sector responds differently to interest rates, economic growth, and inflation. For example, tech and growth‑oriented areas can be more sensitive when rates rise, while defensive sectors like consumer staples often hold up better in rough markets. This portfolio’s mix suggests it can participate in growth themes while still having meaningful exposure to more defensive and income‑oriented sectors.
Regions
- North America 89%
- Europe Developed 5%
- Asia Developed 2%
- Japan 2%
- Asia Emerging 1%
- Australasia 1%
- Latin America 1%
Geographically, the portfolio is strongly US‑centric, with about 89% in North America and only modest exposure elsewhere. Compared with global market weights, this is a clear home bias toward the US, which has helped over the past decade as US stocks outperformed many other regions. Limited allocation to Europe, Japan, and emerging markets means results are tightly linked to the US economy, corporate earnings, and the dollar. That concentration simplifies currency exposure but also means global diversification is not a major driver here. If US markets experience a weaker stretch relative to other regions, this portfolio will feel that more than a globally balanced mix would.
Market capitalization
- Large-cap 36%
- Mega-cap 24%
- Mid-cap 18%
- Small-cap 11%
- Micro-cap 10%
Market‑cap exposure spans the spectrum: about 60% in mega and large caps, 18% mid‑cap, and a meaningful 21% in small and micro caps. Large and mega companies tend to be more stable and dominate broad indices, while small caps can be more volatile but sometimes offer higher growth potential. The dedicated small‑cap value ETF is a big driver of exposure at the lower end of the size range. This blend means performance won’t look exactly like a pure large‑cap index — smaller companies will contribute more to both upside and downside swings than in a typical broad-market fund, adding another layer of diversification within equities.
True holdings
-
AA Apple Inc. 3.54%
Part of fund(s):- Ishares Lifepath Target Date 2055 ETF
- Schwab U.S. Large-Cap Growth ETF
-
NV NVIDIA Corporation 3.41%
Part of fund(s):- Ishares Lifepath Target Date 2055 ETF
- Schwab U.S. Large-Cap Growth ETF
-
MS Microsoft Corporation 2.27%
Part of fund(s):- Ishares Lifepath Target Date 2055 ETF
- Schwab U.S. Large-Cap Growth ETF
-
AM Amazon.com Inc 1.74%
Part of fund(s):- Ishares Lifepath Target Date 2055 ETF
- Schwab U.S. Large-Cap Growth ETF
-
GO Alphabet Inc Class A 1.48%
Part of fund(s):- Ishares Lifepath Target Date 2055 ETF
- Schwab U.S. Large-Cap Growth ETF
-
AB Abbott Laboratories 1.41%
Part of fund(s):- Schwab U.S. Dividend Equity ETF
-
AV Broadcom Inc 1.31%
Part of fund(s):- Ishares Lifepath Target Date 2055 ETF
- Schwab U.S. Large-Cap Growth ETF
-
AM Amgen Inc 1.31%
Part of fund(s):- Schwab U.S. Dividend Equity ETF
-
MR Merck & Company Inc 1.29%
Part of fund(s):- Schwab U.S. Dividend Equity ETF
-
KO The Coca-Cola Company 1.29%
Part of fund(s):- Schwab U.S. Dividend Equity ETF
- Top 10 total 19.05%
Looking through ETF top‑10 holdings, several mega‑cap names appear across multiple funds, including Apple, NVIDIA, Microsoft, Amazon, and Alphabet. Individual exposures to these companies are in the 1–3.5% range, so no single stock dominates the total portfolio. However, because they show up in more than one ETF, their influence is higher than any one fund’s holding list might suggest. Healthcare and defensive names like Abbott, Merck, Amgen, and Coca‑Cola also feature. Coverage statistics show only about a third of the portfolio is captured via disclosed top‑10s, so true overlap is probably a bit higher, but there is no obvious single‑stock concentration risk here.
Factors
Factor exposure stands out most on value, which is at 64%, a mild tilt above the market‑average 50%. Factor exposure is like checking which “ingredients” — such as cheapness, size, or quality — are emphasized. The higher value tilt is mainly driven by the dividend ETF and the small‑cap value fund, both of which focus on companies trading at lower valuations relative to fundamentals. Other factors — size, momentum, quality, yield, and low volatility — sit in the neutral band, meaning they broadly resemble the wider market. Overall, this suggests a gently value‑aware portfolio layered on top of fairly market‑like behavior in other characteristics.
Risk contribution
-
Ishares Lifepath Target Date 2055 ETF
Weight: 30.00% 28.8% -
Schwab U.S. Large-Cap Growth ETF
Weight: 23.00% 27.0% -
Schwab U.S. Dividend Equity ETF
Weight: 30.00% 22.3% -
Avantis® U.S. Small Cap Value ETF
Weight: 17.00% 22.0%
Risk contribution shows how much each ETF drives overall volatility, which can differ from simple weights. The LifePath 2055 fund is 30% of assets and contributes about 29% of risk, so it behaves roughly in line with its size. The large‑cap growth ETF is 23% of the portfolio but adds 27% of risk, while the 17% small‑cap value slice contributes nearly 22% of risk. That means these two growth and small‑cap funds punch above their weight in terms of ups and downs. The dividend ETF, at 30% weight but 22% risk contribution, slightly dampens volatility, acting as a stabilizer relative to the more volatile components.
Risk vs. return
This chart shows the Efficient Frontier, calculated using your current assets with different allocation combinations. It highlights the best balance between risk and return based on historical data. "Efficient" portfolios maximize returns for a given risk or minimize risk for a given return. Portfolios below the curve are less efficient. This is informational and not a recommendation to buy or sell any assets.
Click on the colored dots to explore allocations.
The risk‑return optimization chart shows the current portfolio sitting on or very close to the efficient frontier. The Efficient Frontier is the curve of best possible returns for each risk level using only the existing holdings, just with different weightings. The current Sharpe ratio, 1.23, is below the maximum Sharpe of 1.52, but that “optimal” mix has only slightly lower risk and return. The minimum‑variance version is also efficient, with the highest Sharpe but meaningfully lower expected return. Overall, the current blend is already making good use of these four ETFs, with no obvious signs of inefficient risk that reweighting alone would dramatically improve.
Dividends
- Avantis® U.S. Small Cap Value ETF 1.20%
- Ishares Lifepath Target Date 2055 ETF 1.40%
- Schwab U.S. Dividend Equity ETF 3.10%
- Schwab U.S. Large-Cap Growth ETF 0.40%
- Weighted yield (per year) 1.65%
The overall dividend yield of about 1.65% reflects a blend of a relatively high‑yield dividend ETF at 3.10%, a mid‑range target‑date fund, and much lower‑yielding growth and small‑cap value ETFs. Yield is the cash income paid out each year, before price changes. In this portfolio, dividends play a supporting role rather than being the main return driver. Most long‑term growth is likely to come from price appreciation, especially in the large‑cap growth and small‑cap value slices. At the same time, the dividend ETF provides a steadier income stream, which can help smooth total returns and reduce reliance on selling shares to realize gains.
Ongoing product costs
- Avantis® U.S. Small Cap Value ETF 0.25%
- Ishares Lifepath Target Date 2055 ETF 0.11%
- Schwab U.S. Dividend Equity ETF 0.06%
- Schwab U.S. Large-Cap Growth ETF 0.04%
- Weighted costs total (per year) 0.10%
Total ongoing costs come to about 0.10% per year, based on the weighted average TERs of the four ETFs. TER, or Total Expense Ratio, is the annual fee charged by a fund as a percentage of assets, similar to a small management fee baked into the price. This level of cost is impressively low, especially for a portfolio with a multi‑factor mix of growth, value, dividends, and a glidepath fund. Lower fees mean more of the portfolio’s gross returns stay in the investor’s pocket, and over long periods that small difference compounds meaningfully. From a cost perspective, this setup is a strong foundation.
What next?
Ready to invest in this portfolio?
Select a broker that fits your needs and watch for low fees to maximize your returns.
Create your own report?
Join our community!
Compare your holdings
How much do the funds you hold actually overlap with the ones people weigh them against?
The information provided on this platform is for informational purposes only and should not be considered as financial or investment advice. Insightfolio does not provide investment advice, personalized recommendations, or guidance regarding the purchase, holding, or sale of financial assets. The tools and content are intended for educational purposes only and are not tailored to individual circumstances, financial needs, or objectives.
Insightfolio assumes no liability for the accuracy, completeness, or reliability of the information presented. Users are solely responsible for verifying the information and making independent decisions based on their own research and careful consideration. Use of the platform should not replace consultation with qualified financial professionals.
Investments involve risks. Users should be aware that the value of investments may fluctuate and that past performance is not an indicator of future results. Investment decisions should be based on personal financial goals, risk tolerance, and independent evaluation of relevant information.
Insightfolio does not endorse or guarantee the suitability of any particular financial product, security, or strategy. Any projections, forecasts, or hypothetical scenarios presented on the platform are for illustrative purposes only and are not guarantees of future outcomes.
By accessing the services, information, or content offered by Insightfolio, users acknowledge and agree to these terms of the disclaimer. If you do not agree to these terms, please do not use our platform.
Instrument logos provided by Elbstream.
Help us improve Insightfolio
Your feedback makes a difference! Share your thoughts in our quick survey. Take the survey